PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Войти

Зарегистрироваться
Забыли пароль?

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180816 164629
DJI 0065
20180816 213532
IMG-20170807-WA0029
20180202 170838(0)
20180816 142059
  • Human medicines European public assessment report (EPAR): Ozempic, semaglutide, Date of authorisation: 08/02/2018, Revision: 16, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Obgemsa, vibegron, Date of authorisation: 27/06/2024, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Holoclar, ex vivo expanded autologous human corneal epithelial cells containing stem cells, Date of authorisation: 17/02/2015, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Erleada, apalutamide, Date of authorisation: 14/01/2019, Revision: 17, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Biosimilars Research: Awards
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • FDA Public Meeting: BsUFA III Regulatory Science Program Interim Public Meeting - 09/18/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • What's New Related to Drugs
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Drug Trials Snapshot: ROMVIMZA
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Endothelin Receptor Antagonist REMS Information
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • CDER Manual of Policies & Procedures | MAPP
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Generic Drugs Program Monthly and Quarterly Activities Report
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Human medicines European public assessment report (EPAR): Latuda, lurasidone, Date of authorisation: 21/03/2014, Revision: 28, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-07
  • Human medicines European public assessment report (EPAR): Circadin, melatonin, Date of authorisation: 29/06/2007, Revision: 37, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-07
  • Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.